Citations

Clear

4847 citation(s) found for "Yu, Eric".

Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3
Prudencio, Mercedes , García‐Moreno, Héctor , Jansen‐West, Karen , Al‐Shaikh, Rana Hanna , Gendron, Tania F. , Spiegel, Matthew R. , Carlomagno, Yari , Daughrity, Lillian M. , Song, Yuping , Dunmore, Judith A. , Byron, Natalie, Oskarsson, Björn , Nicholson, Katharine, Staff, Nathan P. , Gorcenco, Sorina , Puschmann, Andreas , Lemos, João , Januário, Cristina , LeDoux, Mark S. , Polke, James, Labrum, Robin, McLoughlin, Hayley S. , Paulson, Henry L. , Onodera, Osamu , Tada, Mari , Kakita, Akiyoshi , Fryer, John Denis , Karremo, Christin, Gomes, Inês , Caviness, John N., Pittelkow, Mark R. , Aasly, Jan , Pfeiffer, Ronald F. , Veerappan, Venka , Eggenberger, Eric , Huang, Josephine F. , Uitti, Ryan J. , Wierenga, Klaas J. , Collazo, I. Vanessa Marin , Tipton, Philip W. , Gerpen, Jay A. van, Blitterswijk, Marka van , Bu, Guojun , Petrucelli, Leonard , Jansen-West, Karen R , Carlomagno, Yari , Daughrity, Lillian M , Dunmore, Judith A , Oskarsson, Björn , Staff, Nathan P , Gorcenco, Sorina , Puschmann, Andreas , Lemos, João , Januário, Cristina , Shakkottai, Vikram , McLoughlin, Hayley S , Paulson, Henry L , Konno, Takuya , Onodera, Osamu , Ikeuchi, T , Tada, Mari , Gomes, Inês , Pittelkow, Mark R , Aasly, Jan , Eggenberger, Eric R, Freeman, William D , Huang, Josephine F , Marin Collazo, Iris V , Tipton, Philip W , van Blitterswijk, Marka , Bu, Guojun , Wszolek, Z.K. , Giunti, Paola , Petrucelli, Leonard , Prudencio, Mercedes , Gendron, Tania F , Hanna Al-Shaikh, Rana , Heckman, Michael G. , Friedman, Joseph H. , Konno, Takuya , Ikeuchi, Takeshi , Freeman, William D. , Wszołek, Zbigniew K.

Mayo Clinic

Science Translational Medicine | October 21, 2020 | Volume: 12 | Issue: 566 | Pages: No page available

10.1126/scitranslmed.abb7086 | PMID 33087504 Get It

PolyQ ATXN3 is a pharmacodynamic marker for SCA3, and a SNP associated with the expanded allele may serve to specifically target mutant ATXN3 .
Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer
Yadav, Siddhartha , LaDuca, Holly , Niguidula, Nancy , Lilyquist, Jenna , Gutierrez, Stephanie, Yussuf, Amal , Davis, Brigette Tippin, Pesaran, Tina , Goldgar, David E. , Dolinsky, Jill S. , Chen, Chen , Polley, Eric C. , Shimelis, Hermela , Na, Jie , Hart, Steven N , Pesaran, Tina , Couch, Fergus J. , Chen, C , Yadav, Siddhartha , Hu, Chunling , Lee, Kun Y. , Hart, Steven N. , Chao, Elizabeth , Couch, Fergus J.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 21, 2020 | Volume: 113 | Issue: 10 | Pages: 1429-1433

10.1093/jnci/djaa167 | PMID 33146377 Get It

Abstract To evaluate the racial and ethnic differences in prevalence of germline pathogenic variants (PVs) and the effect of race and ethnicity on breast cancer (BC) risk among carriers, results of multigene testing of 77 900 women with BC (non-Hispanic White [NHW] = 57 003; Ashkenazi-Jewish = 4798; Black = 6722; Hispanic = 5194; and Asian = 4183) were analyzed, and the frequency of PVs in each gene were compared between BC patients (cases) and race- and ethnicity-matched gnomAD reference controls. Compared with NHWs, BRCA1 PVs were enriched in Ashkenazi-Jews and Hispanics, whereas CHEK2 PVs were statistically significantly lower in Blacks, Hispanics, and Asians (all 2-sided P < .05). In case-control studies, BARD1 PVs were associated with high risks (odds ratio > 4.00) of BC in Blacks, Hispanics, and Asians; ATM PVs were associated with increased risk of BC among all races and ethnicities except Asians, whereas CHEK2 and BRIP1 PVs were associated with increased risk of BC among NHWs and Hispanics only. These findings suggest a need for personalized management of BC risk in PV carriers based on race and ethnicity.
A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade
Corder, Brigette N. , Bullard, Brianna L. , Weaver, Eric A. , Weaver, Eric A , Poland, Gregory A.

Mayo Clinic

Viruses | October 20, 2020 | Volume: 12 | Issue: 10 | Pages: 1186

10.3390/v12101186 | PMID 33092070 Get It

On average, there are 3–5 million severe cases of influenza virus infections globally each year. Seasonal influenza vaccines provide limited protection against divergent influenza strains. Therefore, the development of a universal influenza vaccine is a top priority for the NIH. Here, we report a comprehensive summary of all universal influenza vaccines that were tested in clinical trials during the 2010–2019 decade. Of the 1597 studies found, 69 eligible clinical trials, which investigated 27 vaccines, were included in this review. Information from each trial was compiled for vaccine target, vaccine platform, adjuvant inclusion, clinical trial phase, and results. As we look forward, there are currently three vaccines in phase III clinical trials which could provide significant improvement over seasonal influenza vaccines. This systematic review of universal influenza vaccine clinical trials during the 2010–2019 decade provides an update on the progress towards an improved influenza vaccine.
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel
Kunkle, Brian W. , Schmidt, Michael A. , Klein, Hans‐Ulrich , Hamilton‐Nelson, Kara L., Larson, Eric B., Evans, Denis A., Jager, Phil L. De, Crane, Paul K. , Buxbaum, Joseph D. , Ertekin‐Taner, Nilüfer , Barnes, Lisa L. , Fallin, M. Daniele , Go, Rodney C.P., Obisesan, Thomas O. , Bennett, David A. , Hall, Kathleen, Goate, Alison , Foroud, Tatiana M., Martin, Eden R. , Wang, Li‐San , Byrd, Goldie S. , Haines, Jonathan L. , Schellenberg, Gerard D., Mayeux, Richard , Pericak‐Vance, Margaret A. , Reitz, Christiane, Perrie, M. Adams, Roger, L. Albin, Liana, G Apostolova, Steven, Eschrich, Craig, S , Clinton, T. Baldwin, Robert, C. Barber, Barral, Sandra, Thomas, Gunther, James, T., Gary, W. Beecham, Eileen, H. Bigio, Thomas, D., Blacker, Deborah, Bradley, F. Boeve, James, D. Bowen, Boxer, Adam, James, R. Burke, Jeffrey, Morris, Nigel, J Cairns, Cynthia, M. Carlsson, Regina, M. Carney, Minerva, M. Carrasquillo, David, Hugh-Jones, Dick, Malcom, Dickson, Dennis, W., Doody, Rachelle S., Duara, Ranjan , Kelley, M. Faber, Thomas, Jaya , Kenneth, B., David, W. Fardo, Martin, Roger, Matthew, P. Frosch, Douglas, R. Galasko, Gearing, Marla , Daniel, Hervé, Gilbert, John, R., Robert, C. Green, John, Harding, Ronald, L. Hamilton, Hardy, John , Lindy, E. Harrell, Lawrence, Steve, Ryan, Mary, Matthew, J. Huentelman, Christine, M Hulette, Gail, P. Jarvik, Jin, Lee‐Way, Karydas, Anna, Mindy, J. Katz, John, S., Joel, H. Kramer, James, J. Lah, Andrew, Peter, Richard, B., Constantine, G. Lyketsos, Malamon, John , Daniel, Chammiran , Martiniuk, Frank , Masliah, Eliezer , Wayne, C. McCormick, Susan, M, Andrew, Nesbit M, McDonough, Stefan, Ann., Canfield, Mesulam, Marsel, Bruce, L. Miller, Carol, A. Miller, Thomas, J. Montine, Amanda, J. Myers, John, M. Olichney, Joseph, E. Parisi, Peskind, Elaine R. , Pierce, Aimee, Wayne, W. Poon, Joseph, F. Quinn, Raj, Ashok , Raskind, Murray A. , Reisch, Joan, S., John, M. Ringman, Erik, D. Roberson, Howard, J. Rosen, Donald, R. Royall, Mark, A. Sager, Julie, A. Schneider, Lon, Su, William, W. Seeley, Small, Scott A. , Sonnen, Joshua, A., Robert, Aiko, Rudolph, E. Tanzi, Juan, Caballero, Debby, W. Tsuang, Vivianna, M. Van Deerlin, Badri, Nabeel, Harry, Vanessa, Vonsattel, Jean Paul, Weıntraub, Sandra , Kathleen, A Welsh-Bohmer, Kirk, C W, Thomas, SubinVarghese, Randall, Linnell B., Wu, Chuang‐Kuo, Steven, G. Younkin, Yu, Lei , Yu, Chang‐En , Graff‐Radford, Neill R. , Martinez, Izri, Ayodele, Temitope , Cantwell, Laura B., Jean‐Francois, Melissa, Kuzma, Amanda , Adams, Lonnie D., Chung, Jaeyoon , Jun, Gyungah , Hendrie, Hugh C. , Reiman, Eric M. , Kowall, Neil W. , Golde, Todd E. , Saykin, Andrew J. , Starks, Takiyah D. , Albert, Marilyn S. , Petersen, Ronald , Sano, Mary , Wısnıewskı, Thomas , Vassar, Robert , Kaye, Jeffrey A., Henderson, Victor W. , DeCarli, Charles , LaFerla, Frank M. , Brewer, James B., Miller, Bruce L. , Swerdlow, Russell H. , Paulson, Henry L. , Trojanowski, John Q. , Chui, Helena C., Rosenberg, Roger N., Craft, Suzanne , Grabowski, Thomas J. , Asthana, Sanjay , Morris, John C. , Strittmatter, Stephen M. , Kukull, Walter A. , Asthana, Sanjay , Jarvik, Gail P. , Cribbs, David H. , Sonnen, Joshua A. , Bennett, David A. , Saykin, Andrew J , Miller, Bruce L , Jarvik, Gail P , Paulson, Henry L , Hardy, John , Morris, John C , Goate, Alison M , Sonnen, Joshua , Barnes, Lisa L , Naj, Adam Christian , Hamilton‐Nelson, Kara L. , Manly, Jennifer J. , Kamboh, M. Ilyas , Farrer, Lindsay A. , Abner, Erin L. , Atwood, Craig, S., Becker, James, T., Eileen, H Bigio, Blacker, Deborah , Cao, Chuanhai , Cruchaga, Carlos , Dickson, Dennis, W., Duara, Ranjan , David, W. Fardo, Farlow, Martin, R., Ferris, Steven H. , Geschwind, Daniel, H., Ghetti, Bernardino , Gilbert, John, R., Håkonarson, Håkon , Honig, Lawrence, S., Huebinger, Ryan, M., Matthew, J Huentelman, Kauwe, John, S.K., Keene, C. Dirk , Kim, Ronald, Leung, Yuk Yee , Li, Ge , Lipton, Richard, B., Marson, Daniel, C., McDavid, Andrew, N., Mesulam, Marsel M. , Bruce, L Miller, Mukherjee, Shubhabrata , O’Bryant, Sid, E., Potter, Huntington , Qu, Liming , Raj, Ashok, Reisberg, ‌Barry , Reisch, Joan, S., Rogaeva, Ekaterina A. , Julie, A Schneider, Schneider, Lon, S., William, W Seeley, Spina, Salvatore , George‐Hyslop, Peter St , Valladares, Otto , Vardarajan, Badri, N., Wilhelmsen, Kirk, C., Williamson, Jennifer , Wingo, Thomas, S., Woltjer, Randall, L., Steven, G Younkin, Zhao, Yi Chen , Logue, Mark W. , Adams, L.D., Vance, Jeffery M. , Cuccaro, Michael L. , Mez, Jesse , Lunetta, Kathryn L. , López, Oscar L. , Leverenz, James B. , Levey, Allan I. , Hyman, Bradley T. , Kaye, Jeffrey A., Eldik, Linda J. Van , Chui, Helena C.

Mayo Clinic

JAMA Neurology | October 19, 2020 | Volume: 78 | Issue: 1 | Pages: 102

10.1001/jamaneurol.2020.3536 | PMID 33074286 Get It

Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate
Hall, William A. , Fishbane, Nick , Xu, Melody, Davicioni, Elai , Den, Robert B. , Dess, Robert T. , Wong, Anthony , Schaeffer, Edward M. , Karnes, R. Jeffrey , Kim, Hyung L. , Klein, Eric A. , Davis, John W. , Ross, Ashley E. , Tosoian, Jeffrey J. , Mehra, Rohit , Salami, Simpa S. , Nguyen, Paul L. , Lawton, C.A., Spratt, Daniel E. , Feng, Felix Y. , Xu, Melody J , Davicioni, Elai , Den, Robert B , Dess, Robert T , Jackson, William C , Wong, Anthony C , Carroll, Peter R , Bismar, Tarek A , Kim, Hyung L , Klein, Eric A , Tosoian, Jeffrey J , Morgan, Todd M , Salami, Simpa S , Spratt, Daniel E , Liu, Yang , Mahal, Brandon A. , Jackson, Will , Cooperberg, Matthew R , Morgan, Todd M.

Mayo Clinic

JCO Precision Oncology | October 16, 2020 | Volume: No volume available | Issue: 4 | Pages: 1228-1238

10.1200/po.20.00013 | PMID 35050780 Get It

PURPOSE Pretreatment estimates of seminal vesicle invasion (SVI) are challenging and significantly influence the management of prostate cancer. We sought to improve current models to predict SVI through the development of an SVI prediction genomic signature. PATIENTS AND METHODS A total of 15,889 patients who underwent radical prostatectomy (RP) with available baseline clinical, pathology, and transcriptome data were retrieved from the GRID registry (ClinicalTrials.gov identifier: NCT02609269 ) and other retrospective cohorts. These data were divided into a training (n = 6,766), test (n = 3,363), and two validation (n = 5,062 and 698) cohorts. Multivariable logistic regression was performed to assess the predictive effect of the genomic SVI (gSVI) classifier in the presence of established nomograms (Partin Tables and Memorial Sloan Kettering Cancer Center [MSKCC]). RESULTS In the training cohort, univariable filtering identified 2,132 genes that were differentially expressed between RP tumors with and without SVI. Model parameters were tuned to maximize the area under the curve (AUC) in the testing cohort, resulting in a logistic generalized linear model with 581 genes. The gSVI model scores range from 0 to 1. In the first validation set, gSVI showed superior discrimination of patients with and without SVI at RP compared with other prognostic signatures trained to predict distant metastasis or clinical recurrence. Of the 698 patients in the second validation set, gSVI combined with the MSKCC nomogram had a superior AUC (0.86) compared with either nomogram individually (0.81). CONCLUSION The gSVI represents a novel and validated expression signature to predict the presence of SVI before treatment with surgery. This genomic tool adds discriminatory power to existing clinical predictive nomograms and may help with pretreatment counseling and decision making.
Expansion of PURA -Related Phenotypes and Discovery of a Novel PURA Variant: A Case Report
Boczek, Nicole J. , Macke, Erica L. , Kemppainen, Jennifer L., Klee, Eric W. , Renaud, Deborah L. , Gavrilova, Ralitza H. , Kemppainen, Jennifer, Renaud, Deborah

Mayo Clinic

Child Neurology Open | October 14, 2020 | Volume: 7 | Issue: No issue available | Pages: 2329048X2095500

10.1177/2329048x20955003 | PMID 33117858 Get It

Variants in PURA have recently been associated with an autosomal dominant form of PURA-related neurodevelopmental disorders. Using whole exome sequencing, patients with neurological phenotypes including hypotonia, developmental delay, learning disabilities, and seizures were identified to have de novo variants in PURA. We describe a proband with features similar to the previously described cases with PURA variants, but including additional features, such as short stature, delayed bone age, and delayed puberty. Exome sequencing revealed a novel pathogenic nonsense variant, c.190A>T (p.Lys64*; NM_005859), in PURA that was not inherited from the proband’s mother. In the recent literature, a significant number of patients with variants in PURA have been described, but to our knowledge, none of these patients have the delayed bone age and growth plateau observed in the proband. It is therefore possible that the above PURA variant may be responsible for the novel features and thus expands the PURA-related phenotype spectrum.
The COVID-19 Pandemic Impact on Cardio-Oncology: Results From the COVID-19 International Collaborative Network Survey.
Sadler, Diego , DeCara, Jeanne M. , Herrmann, Joerg , Arnold, Anita , Leja, Monika, Silva, Carolina Maria Pinto Domingues Carvalho, O’Quinn, Rupal , Moudgil, Rohit , Raez, Luis M., Okwuosa, Tochukwu, Daniele, Andrés J., Bauer, Brenton , Ismail‐Khan, Roohi , Nahleh, Zeina , Baldassarre, Lauren A. , Rao, Vijay, Lara, Daniel Sierra, Skurka, Kerry, Sadler, Diego , Ghosh, Arjun K. , Abdel-Qadir, Husam Mohamed , Yang, Eric H. , Szmit, Sebastian , Akhter, Nausheen , Raikhelkar, J. , Brown, Sherry‐Ann , Thuny, Franck , Kondapalli, Lavanya , Lax, Jorge Alberto , Blaes, Anne , Elson, Leah C. , Zaha, Vlad G , Dent, Susan

Mayo Clinic

No container title available | October 12, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-88776/v1 Get It

Abstract BackgroundRe-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care in this setting has not been formally evaluated.ObjectivesTo assess the impact of COVID-19 resource re-allocation on scheduling, testing, elective procedures, telemedicine access, use of new COVID-19 therapies, and providers’ opinions on healthcare policies among oncology and cardiology practitioners.MethodsAn electronic survey was conducted by a cardio-oncology collaborative network through regional and state chapters of the American College of Cardiology , American Society of Clinical Oncology, and the International Cardio-Oncology Society. Descriptive statistics were reported by frequency and proportion for analyses, and stratified categorically by geographic region and specialty.Results1,415 providers (43 countries) participated: 986 cardiologists, 306 oncologists, and 118 trainees/internal medicine. 63% (195/306) of oncologists vs 92% (896/976) of cardiologists reported cancellations of treatments/elective procedures (p=0.01). 46% (442/970) of cardiologists and 25% (76/303) of oncologists modified the scope of their practice (p=<0.001). Academic physicians (74.5%) felt better supplied with personal protective equipment (PPE) vs non-academic (74.5% vs 67.2%; p=0.018). Telemedicine was less common in Europe 81% (74/91), and Latin America 64% (101/158), than the United States, 88% (950/1,097) (p=<0.001). 95% of all groups supported more active leadership from medical professional societies.ConclusionsThese results support initiatives to promote expanded coverage for telemedicine, increased access to PPE, better testing availability and involvement of medical professional societies to help with preparedness for future health care crisis.Appendix: Link to the Survey: https://www.surveymonkey.com/r/C8ZDYNW
Immune dysfunction in MGAT2‐CDG: A clinical report and review of the literature
Poskanzer, Sheri A. , Turgeon, Coleman , Vidal‐Folch, Noemi, Liedtke, Kris L., Oglesbee, Devin , Gavrilov, Dimitar K. , Tortorelli, Silvia , Matern, Dietrich , Rinaldo, Piero, Thies, Jenny , Chang, Irene J. , Beck, Anita E. , Raymond, Kimiyo , Lam, Christina , Turgeon, Coleman T, Vidal-Folch, Noemi, Liedtke, Kris, Bennett, James T , Thies, Jenny M , Chang, Irene J , Beck, Anita E , Raymond, Kimiyo , Allenspach, Eric J , Lam, Christina , Oglesbee, Devin , Poskanzer, Sheri A , Schultz, Matthew , Liedtke, Kristen

Mayo Clinic

American Journal of Medical Genetics Part A | October 12, 2020 | Volume: 185 | Issue: 1 | Pages: 213-218

10.1002/ajmg.a.61914 | PMID 33044030 Get It

AbstractGlycosylation is a critical post/peri‐translational modification required for the appropriate development and function of the immune system. As an example, abnormalities in glycosylation can cause antibody deficiency and reduced lymphocyte signaling, although the phenotype can be complex given the diverse roles of glycosylation. Human MGAT2 encodes N‐acetylglucosaminyltransferase II, which is a critical enzyme in the processing of oligomannose to complex N‐glycans. Complex N‐glycans are essential for immune system functionality, but only one individual with MGAT2‐CDG has been described to have an abnormal immunologic evaluation. MGAT2‐CDG (CDG‐IIa) is a congenital disorder of glycosylation (CDG) associated with profound global developmental disability, hypotonia, early onset epilepsy, and other multisystem manifestations. Here, we report a 4‐year old female with MGAT2‐CDG due to a novel homozygous pathogenic variant in MGAT2, a 4‐base pair deletion, c.1006_1009delGACA. In addition to clinical features previously described in MGAT2‐CDG, she experienced episodic asystole, persistent hypogammaglobulinemia, and defective ex vivo mitogen and antigen proliferative responses, but intact specific vaccine antibody titers. Her infection history has been mild despite the testing abnormalities. We compare this patient to the 15 previously reported patients in the literature, thus expanding both the genotypic and phenotypic spectrum for MGAT2‐CDG.
Risk factors for carcinoma ex pleomorphic adenoma in patients presenting with recurrence after resection of pleomorphic adenoma
Abel, Kathryn M. Van , Rooker, Steven A. , Nagelschneider, Alex A. , Olsen, Kerry D., Janus, Jeffrey R. , Kasperbauer, Jan L. , Moore, Eric J. , Yin, Linda X , Van Abel, Kathryn M , Rooker, Steven A , Moore, Eric J , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

Head & Neck | October 12, 2020 | Volume: 43 | Issue: 2 | Pages: 419-427

10.1002/hed.26489 | PMID 33043539 Get It

AbstractBackgroundIn patients presenting with recurrent pleomorphic adenoma (rPA), clinical evaluation can fail to recognize carcinoma ex PA (cxPA). We aim to identify the risk factors for cxPA.MethodsThis is a single institution retrospective case‐control study from 2000 to 2015. CxPA was diagnosed based on surgical pathology. Demographics, clinical, and social histories were collected.ResultsA number of 13/106 (12.3%) patients were diagnosed with cxPA, of which only 4/13 (31%) had clinical features suspicious for malignancy. Compared to benign rPA, factors associated with cxPA included age >50 (odds ratio [OR] 6.67, 95% confidence interval [CI]: 1.71‐25.98, P < .01), >10 pack‐years of smoking history (OR 3.36, 95% CI: 1.01‐11.14, P = .04), and the largest tumor being >2 cm on pathology (OR 4.42, 95% CI: 1.14‐17.10, P = .03).ConclusionsIn patients presenting with rPA, risk factors for malignant transformation include age >50, significant smoking history, and tumors larger than 2 cm. Clinical signs of malignancy such as rapid growth or pain are not always present.
Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Awasthi, Shivanshu , Berglund, Anders , Abraham-Miranda, Julieta , Rounbehler, Robert J., Kensler, Kevin H. , Serna, Amparo , Vidal, Adriana C. , You, Sungyong , Freeman, Michael R. , Karnes, R. Jeffrey , Klein, Eric A. , Campbell, Joshua D. , Gupta, Raavi , Lal, Priti , Freedland, Stephen J. , Kensler, Kevin , Den, Robert B , Trock, Bruce J , Campbell, Joshua D , Einstein, David J , Balk, Steven , Park, Jong Y , Yamoah, Kosj , Klein, Eric A , Berglund, Anders E , Davicioni, Elai , Liu, Yang , Den, Robert B. , Balk, Steven P. , Park, Jong Y. , Cleveland, John L. , Rebbeck, Timothy R.

Mayo Clinic

Clinical Cancer Research | October 9, 2020 | Volume: 27 | Issue: 1 | Pages: 320-329

10.1158/1078-0432.ccr-20-2925 | PMID 33037017 Get It

Abstract Purpose: The role of immune-oncologic mechanisms of racial disparities in prostate cancer remains understudied. Limited research exists to evaluate the molecular underpinnings of immune differences in African American men (AAM) and European American men (EAM) prostate tumor microenvironment (TME). Experimental Design: A total of 1,173 radiation-naïve radical prostatectomy samples with whole transcriptome data from the Decipher GRID registry were used. Transcriptomic expressions of 1,260 immune-specific genes were selected to assess immune-oncologic differences between AAM and EAM prostate tumors. Race-specific differential expression of genes was assessed using a rank test, and intergene correlational matrix and gene set enrichment was used for pathway analysis. Results: AAM prostate tumors have significant enrichment of major immune-oncologic pathways, including proinflammatory cytokines, IFNα, IFNγ, TNFα signaling, ILs, and epithelial–mesenchymal transition. AAM TME has higher total immune content score (ICSHIGH) compared with 0 (37.8% vs. 21.9%, P = 0.003). AAM tumors also have lower DNA damage repair and are genomically radiosensitive as compared with EAM. IFITM3 (IFN-inducible transmembrane protein 3) was one of the major proinflammatory genes overexpressed in AAM that predicted increased risk of biochemical recurrence selectively for AAM in both discovery [HRAAM = 2.30; 95% confidence interval (CI), 1.21–4.34; P = 0.01] and validation (HRAAM = 2.42; 95% CI, 1.52–3.86; P = 0.0001) but not in EAM. Conclusions: Prostate tumors of AAM manifest a unique immune repertoire and have significant enrichment of proinflammatory immune pathways that are associated with poorer outcomes. Observed immune-oncologic differences can aid in a genomically adaptive approach to treating prostate cancer in AAM.